Stay updated on LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial
Sign up to get notified when there's something new on the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page.

Latest updates to the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page
- Check2 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, signaling a backend or template update. This update does not modify the study content or user-facing information on the page.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAdded new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and updated the Intervention/Treatment heading; the old Intervention / Treatment label and the previous Revision note (Revision: v3.5.5) were removed, aligning with the new v3.6.0 revision.SummaryDifference0.5%

- Check24 days agoChange DetectedRevision label on the page changes from v3.5.4 to v3.5.5. This reflects a metadata/version update and does not alter the visible content.SummaryDifference0.1%

- Check45 days agoChange DetectedA new revision label (v3.5.4) replaces the previous v3.5.3, indicating a backend or display update without changing the study information presented on the page.SummaryDifference0.1%

- Check67 days agoChange DetectedThe page’s footer revision label was updated from v3.5.2 to v3.5.3, reflecting a platform/version update without changing the underlying study details.SummaryDifference0.1%

- Check74 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

Stay in the know with updates to LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LowDose IL-2 & Pembrolizumab in Melanoma/RCC Clinical Trial page.